- Home
- VEEA vs BMEA Comparison
VEEA vs BMEA Comparison
Compare VEEA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEA
- BMEA
- Stock Information
- Founded
- VEEA 2014
- BMEA 2017
- Country
- VEEA United States
- BMEA United States
- Employees
- VEEA N/A
- BMEA N/A
- Industry
- VEEA
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- VEEA
- BMEA Health Care
- Exchange
- VEEA NYSE
- BMEA Nasdaq
- Market Cap
- VEEA 137.7M
- BMEA 145.0M
- IPO Year
- VEEA N/A
- BMEA 2021
- Fundamental
- Price
- VEEA $3.66
- BMEA $3.98
- Analyst Decision
- VEEA
- BMEA Buy
- Analyst Count
- VEEA 0
- BMEA 13
- Target Price
- VEEA N/A
- BMEA $27.92
- AVG Volume (30 Days)
- VEEA 67.4K
- BMEA 939.5K
- Earning Date
- VEEA 02-23-2025
- BMEA 10-29-2024
- Dividend Yield
- VEEA N/A
- BMEA N/A
- EPS Growth
- VEEA N/A
- BMEA N/A
- EPS
- VEEA N/A
- BMEA N/A
- Revenue
- VEEA $140,035.00
- BMEA N/A
- Revenue This Year
- VEEA N/A
- BMEA N/A
- Revenue Next Year
- VEEA N/A
- BMEA N/A
- P/E Ratio
- VEEA N/A
- BMEA N/A
- Revenue Growth
- VEEA N/A
- BMEA N/A
- 52 Week Low
- VEEA $2.14
- BMEA $3.61
- 52 Week High
- VEEA $18.56
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- VEEA N/A
- BMEA 35.19
- Support Level
- VEEA N/A
- BMEA $3.78
- Resistance Level
- VEEA N/A
- BMEA $4.29
- Average True Range (ATR)
- VEEA 0.00
- BMEA 0.29
- MACD
- VEEA 0.00
- BMEA 0.14
- Stochastic Oscillator
- VEEA 0.00
- BMEA 49.26
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.